Compare ALKT & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALKT | DMRA |
|---|---|---|
| Founded | 2007 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 2021 | 2020 |
| Metric | ALKT | DMRA |
|---|---|---|
| Price | $14.43 | $20.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 10 |
| Target Price | $19.86 | ★ $46.89 |
| AVG Volume (30 Days) | ★ 2.0M | 519.7K |
| Earning Date | 10-28-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 121.48 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $152,159,000.00 | N/A |
| Revenue This Year | $19.44 | N/A |
| Revenue Next Year | $16.64 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 35.68 | N/A |
| 52 Week Low | $13.21 | $16.50 |
| 52 Week High | $24.47 | $34.89 |
| Indicator | ALKT | DMRA |
|---|---|---|
| Relative Strength Index (RSI) | 33.03 | 40.58 |
| Support Level | $13.21 | $18.73 |
| Resistance Level | $14.52 | $26.76 |
| Average True Range (ATR) | 0.48 | 1.36 |
| MACD | 0.13 | 0.16 |
| Stochastic Oscillator | 35.16 | 50.46 |
Alkami Technology Inc is a cloud-based digital banking solutions provider. The company offers the Alkami Digital Sales & Service Platform, which includes a digital banking platform, onboarding and account opening solutions, and data and marketing tools. The platform enables financial institutions to onboard and engage users, support revenue growth, and improve operational efficiency through a cloud-based, multi-tenant architecture. The company provides services to clients under software-as-a-service arrangements. It derives substantially all of its revenues from SaaS subscription services charged for the use of digital sales and service solutions.
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.